Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

BACKGROUND Somatic mutations accumulate in normal tissues as a function of time. The
great majority of these mutations have no effect on fitness, so selection does not act upon …

Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …

Clonal expansions driven by somatic mutations become pervasive across human tissues
with age, including in the haematopoietic system, where the phenomenon is termed clonal …

Abstract Tumor protein p53 (TP53) is the most frequently mutated gene in cancer,. In
patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high …

PURPOSE Therapeutically actionable molecular alterations are widely distributed across
cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …

TP53 is the most frequently mutated gene in human cancer. Functionally, p53 is activated by
a host of stress stimuli and, in turn, governs an exquisitely complex anti-proliferative …

A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show
complex karyotype (CK), and these cases include a relatively high proportion of cases of …